Complex Diseases, Success and Failure

Finding the „right" target → valid targets

which constrains are limiting factors?

Dosage, bioavailability, actual drug concentration in the respective compartment (cell, organelles)

Are we competing against a natural substrate, e.g. ATP ? (concentration in the cell: ca. 4 mMol)

Biological barriers: e.g. bacterial cell walls

Picture source: N.L.Brown et al.
Nature Rev. Biology (2015)
DOI:10.1038/nrmicro3480

Success

Antifungals

Ketoconazole, Fluconazole, Itraconazole, Clotrimazole, ...

Mechanism of action: Inhibition of 14-α-demethylase (CYP51) that is part of the biosynthesis pathway of ergosterol, which is an essential component of the fungal cell membrane (in mammals: cholesterol).

ergosterol

cholesterol

Cons: Inhibition of Cytochromes causes hepatotoxicity (e.g. ketoconazole). Other conazoles are more specific.
Development of resistances (overexpression of efflux proteins).

Failure (so far) (I)

Antibacterial agents targeting enzymes of the Shikimate pathway (responsible for the synthesis of the amino acids Phe, Tyr, and Trp).

shikimate ← ← Phosphoenolpyruvate (PEP) + erythrose-4-phosphate

shikimate kinase

biodegradation

glyphosate (herbicide)

chorismate synthase

5-enolpyruvylshikimate-3-phosphate synthase (EPSPS)   chorismate

Pro: Those enzymes are only found in plants, fungi, algae, and bacteria but not in mammals. Thus interference can be ruled out.

Failure (so far) (II)

Chorismate mutase — Prephenate → Phenylalanine

Anthranylate → → Tyrosine

Pathogens such as *Oxoplasma gondii*, *Plasmodium falciparum,* and *Cryptosporidium parvum* contain the Shikimate pathway and the seven enzymes involved.

Lit. C.W.Roberts et al. *J.Infect.Dis.* **185** (2002) Suppl.1:S25-36.

Con: Obviously the neccessary inhibitor concentration in the respective compartment could not be achieved.
For comparison:
The cellular level of phosphoenolpyruvate (PEP) is ca. 4 mMol

Complex Diseases

malaria is the tropical disease no.1

300-500 millionen infections per year
causing 1-3 million fatalities

clinical symptoms:

Strong fever, anemia, acidosis,
multiple failure of organs

Due to the life cycle of the pathogen *Plasmodium flaciparum,*
and the transmission by the *anopheles* fly, there are several
starting points for control and therapy.

Lit. D.A.Fidock et al. *Nature Rev. Drug Disc.* **3** (2004) 509

malaria pathogens cause degradation of hemoglobin

Red blood cell

Apicoplast
Drug:
Antibiotics
New targets:
Plastid DNA replication and transcription;
type 2 fatty acid biosynthesis;
non-mevalonate isoprenyl biosynthesis

Food vacuole
Drug:
4-aminoquinolines; artemisinins?
New targets:
Falcipains and plasmepsins

Cytosol
Drug:
Antifolates; artemisinins?
New targets:
Glycolysis; protein kinases

Haemozoin

Tubovesicular network

Early vacuole

Cytostome

Golgi complex

Parasitophorous vacuole

Plasma membrane

Free ribosome

Mitochondrion
Drug:
Atovaquone

Nucleus

Rough ER

Plasmodium falciparum trophozoite

Further pathogens in human:

P. vivax
P. malariae
P. ovale

and about 56 more species of *Plasmodium*

Nature Reviews | Drug Discovery

Lifecylce of the malaria pathogens

source: http://www.dpd.cdc.gov/.../body_Malaria_page1.htm

Approaches to controlling (I)

1960-1980 exhaustive use of insecticides against the Anopheles fly with very good results by the use of DDT (dichloro-diphenyl-trichloroethane)

Disadvantages:

• Accumulation of DDT in the adipose tissue [Fettgewebe] of all creatures (mammals, birds, fish)

• DDT is biologically (almost) undegradable

• Metabolismus leads to a neurotransmitter-like substance (acts as contact insecticide !)

DDT

DDE (antiandrogen)

• Increasing resistance to DDT has been observed

Distribution of Malaria (I)

Areas with risk of malaria

Distribution of malaria (II)

Distribution of actual and potential malaria transmission stability

Stability index
- 0
- 0.00 - 0.05
- 0.05 - 1.00
- 1.00 - 2.00
- 2.00 - 5.00
- 5.00 - 10.00
- 10.00 - 15.00
- 15.00 - 25.00
- 25.00 - 38.00

Figure 1 from Anthony Kiszewski, Andrew Mellinger, Andrew Spielman, Pia Malaney, Sonia Erlich Sachs, and Jeffrey Sachs. **A Global Index Representing The Stability of Malaria Transmission**. Am J Trop Med Hyg 2004 70:486-498.

Distribution of the Anopheles fly

Dominant malaria vectors (Anopheles)

Figure 1 from Anthony Kiszewski, Andrew Mellinger, Andrew Spielman, Pia Malaney, Sonia Erlich Sachs, and Jeffrey Sachs. A Global Index Representing The Stability of Malaria Transmission. Am J Trop Med Hyg 2004 70:486–498.

Approaches to controlling (II)

chloroquine: since the late 1940's worldwide application at
very low costs (0.2 US$ per dose)

mode of action (still partly unclear):
binds to HEM groups
inhibition of the glutathion-S-transferase

sulfadoxine
antibacterial

pyrimethamine
blocks the dihydrofolate reductase
respectively the dihydropterate synthetase

Resistance of the Anopheles fly

Chloroquine resistance
Chloroquine + sulphadoxine-pyrimethamine resistance

Nature Reviews | Drug Discovery

red: areas with malaria

Approaches to contolling (III)

Alternatives to chloroquine and sulfadoxine/pyrimethamine

amodiaquine respectively chlorproguanil/dapsone

Disadvantage: expected build up of resistances due to identical targets

Approaches to contolling (IV)

Profile for new drugs and chemoprophylaxis

• efficient, cheap

• effective against the more rare, but lethal *Plasmodium vivax*

• Avoiding of restistances by the use of combinations drugs (several targets at the same time)

Example for chemoprophylaxis: mefloquine (Lariam®)

Mode of action due to interaction with phospholipids (cell membrane, fatty acid synthesis)

Only very few adverse effects

Approaches to controlling (V)

Example for combination drugs:
atovaquone (antiparasitic) together with an antibiotic

Drugs derived from natural compounds:
artemisinin → artemether and artesunate (form cytotoxic radicals in the presence of HEM iron)

Disdavantage: rapid metabolization and thus short half life

New malaria targets (I)

Table 2 | Targets for antimalarial chemotherapy

Target location	Pathway/mechanism	Target molecule	Examples of therapies Existing therapies	New compounds	References
Cytosol	Folate metabolism	Dihydrofolate reductase Dihydropteroate synthase	Pyrimethamine, proguanil Sulphadoxine, dapsone	Chlorproguanil	82,83
	Glycolysis	Thymidylate synthase		5-fluoroorotate	84
		Lactate dehydrogenase		Gossypol derivatives	85
		Peptide deformylase		Actinonin	86
	Protein synthesis	Heat-shock protein 90		Geldanamycin	87
	Glutathione metabolism	Glutathione reductase		Enzyme inhibitors	88
	Signal transduction	Protein kinases		Oxindole derivatives	89
	Unknown	Ca^{2+}-ATPase	Artemisinins		90
Parasite membrane	Phospholipid synthesis	Choline transporter		G25	71
	Membrane transport	Unique channels	Quinolines	Dinucleoside dimers	91
		Hexose transporter		Hexose derivatives	92
Food vacuole	Haem polymerization	Haemozoin	Chloroquine	New quinolines	93,94
	Haemoglobin hydrolysis	Plasmepsins		Protease inhibitors	95,96
		Falcipains		Protease inhibitors	97,98
	Free-radical generation	Unknown	Artemisinins	New peroxides	99,100
Mitochondrion	Electron transport	Cytochrome c oxidoreductase	Atovaquone		101
Apicoplast	Protein synthesis	Apicoplast ribosome	Tetracyclines, clindamycin		102
	DNA synthesis	DNA gyrase	Quinolones		
	Transcription	RNA polymerase	Rifampin		
	Type II fatty acid bio-synthesis	FabH		Thiolactomycin	29
		FabI/PfENR		Triclosan	32,33,103
	Isoprenoid synthesis	DOXP reductoisomerase		Fosmidomycin	30
	Protein farnesylation	Farnesyl transferase		Peptidomimetics	25,104
Extracellular	Erythrocyte invasion	Subtilisin serine proteases		Protease inhibitors	97,105

DOXP, 1-deoxy-D-zylulose 5-phosphate; PfENR, *Plasmodium falciparum* enoyl-ACP reductase.

Lit. D.A.Fidock et al. *Nature Rev. Drug Disc.* **3** (2004) 509

New malaria targets (II)

→ Target identification on the gene level
    homolog enzymes of known diseases

→ Improvment of drugs that are already in use against other
  (infective) diseases:

dihydrofolate reductase   → cancer

cysteine protease   → osteoporosis

protein farnesyl transferase   → cancer

protein synthesis   → other parasites

vaccines: proteins that are expressed on the cell surface
→ sequencing of the *Plasmodium falciparum* genome

(New) malaria drugs and targets (as of 2018)

Target	Drug
Fe(II)protoporphyrin IX	mefloquine
Fe(II)protoporphyrin IX	primaquine
Ferredoxin-NADPH reductase	tafenoquine (approved)
Dehydroorotate dehydrogenase	atovaquone
Dehydroorotate dehydrogenase	DSM265 (phase II)
Posphatidylinositol-4 kinase	MMV390048 (phase II)
Glutathione S-transferase	artesunate
Glutathione S-transferase	artefenomel (phase II)
Mitochondrial Enlogation Factor G	M7517 (phase I)
Ca^{2+} transporting P-ATPase 4	cipargamin (phase II)

New malaria targets (III)

Sequencing of *Plasmodium falciparum*

25 Mb on 14 chromosomes, ca. 5000 genes
  6 Kb genome of the mitochondrium
35 Kb circular DNA of the Apicoplast

Similar dimensions are also to be expected
for *P. yoelii* and *P. vivax*.

http://www.ncbi.nlm.hih.gov/Malaria/

http://plasmodb.org (annotated Plasmodium genome)

Metabolic paths of *P. falciparum*:

http://sites.huji.ac.il/malaria/ (contains EC numbers)

Lit. S.L.Hoffman et al. *Nature* **415** (2002) 702

Neglected Tropical Diseases (I)

Infections with pathogens prevalent in developping regions around the tropical belt of Africa, Asia, and America.

ascariasis, trichuriasis, necatoriasis, ancyclostomiasis
      infection by soil transmitted helmintics (worms)

Schistosomiasis (snail fever, bilharzia)

Trachoma and onchoceriasis (river blindness)

Leishmanias

Chagas disease

Leprosy

African Trypanosomnias
(sleeping sickness)

The impact of this diseases in numbers is similar to that of malaria and tuberculosis

Neglected Tropical Diseases (II)

The World Health Organisation lists further diseases, such as

Cysticerosis (infection by the pork tapeworm)

Dengue / dengue haemorrhagic fever
              (virus transmitted by mosquitos)

Rabis [Tollwut] (viral)

Yaws (bacterial) a similar treponemal disease is syphillis

Snake bites

Tropical diseases with outbrakes in other areas due to transmission by mosquitos:

West Nile virus

Ross River fever

Complex diseases

obesity [Fettleibigkeit]

typical symptoms:

• excess weight

• increased levels of chlolesterol
  → arteriosclerosis

• hypertension

} increased
cardiovascular
risc

The connection to obesity has been established by the genetic lack of cholesterol receptors (hypercholesterolaemia) and especially cholesterol-rich nutrition in animal studies.

Regulation of the cholesterol pool

Lit. F.Rinninger & H.Greten *Dtsch. Ärztebl.* **102** (2005) A516
J.A.Tobert *Nature Rev. Drug Disc.* **2** (2003) 517

Inhibition of HMG-CoA reductase (I)

compactin (from *Penicillium citrinum*) and mevinolin (=lovastatin) (from *Aspergillus terreus*) were first found as inhibitors.

lovastatin

compactin

Lit. J.A.Tobert *Nature Rev. Drug Disc.* **2** (2003) 517

Inhibition of HMG-CoA reductase (II)

The actually effective substance is the metabolite

HMG-CoA

mevalonic acid

HMG-CoA Reductase

cholesterol biosynthesis

$K_i = 1$ nM

lovastatin

ester cleavage

mevinolin

active metabolite

Sales potential of Statins

Market volume of cholesterol reducing agents

Turnover in billion US$ for USA, France, Germany, Italy, Spain, England and Japan, (market volume in %)
CEPT= cholesteryl ester transferase protein

Lit. J.Quirk et al. *Nature Rev. Drug Disc.* **2** (2003) 769

# Further statins

cerivastatin (Bayer)

simvastatin (Merck & Co)

pravastatin (Sankyo)

fluvastatin (Sandoz)

rosuvastatin (Astra-Zeneca)

atorvastatin (Warner-Lambert)

Further lipid lowering agents (I)

ezetimib inhibits the cholesterol transporter

Lit. Van Heek *Brit.J.Pharmacol.* **129** (2000) 1748.

Further lipid lowering agents (II)

avasimibe inhibits the acetyl-coenzyme-A-cholesterol-acetyltransferase (ACAT-inhibitor)

Further lipid lowering agents (III)

competitive cholesterol analogs

cholesterol

furazabol

clomestrone

Further lipid lowering agents (IV)

Bile acid sequestrants

Polymers that are not absorbed from the intestine

cholestyramine MW>10^6

colestipol

absorb cholesterol and bile acid and therefore prevent uptake of cholesterol

Opinion drugs vs. life style modification

„obesity is a form of depression in which the eating
is an antidepressant"

Fat storage is most efficient to preserve energy

Anorexic drugs (I)

Due to their complex affinity profile regarding a whole series of receptors („dirty drugs") psychoactive drugs also modify the eating behaviour

Lit. B.L.Roth et al.
Nature Rev. Drug Disc. **3** (2004) 353.

Anorexic drugs (II)

Prominent examples of psychoactive drugs with mit appetite suppressant (side-) effect:

methylphenidate (Ritalin®)   ADHD

atomexetine (Strattera®)   [Aufmerksamkeitsdefizitsyndrome]

fluoxetin (Prozac®)

Nature Reviews | Drug Discovery

Market volume of ADHD pharmaca in million US $

Lit. M.Garland, P.Kirkpatrick *Nature Rev. Drug Disc.* **3** (2004) 385.

Prodrugs

Actually effective substance is the main metabolite of the drug

Example: ester cleavage

acetylsalicylic acid   salicylic acid

Irreversible inhibitor of cycloxygenase (COX)

Statins as HMG-CoA Reductase Inhibitors

The prodrug is a lactone whereas its metabolite is effective

HMG-CoA

HMG-CoA
Reductase

mevalonic acid

cholesterol
biosynthesis

$K_i = 1$ nM

lovastatin

mevinolin

active metabolite

Antiviral Nucleoside Analogs

Nucleosides missing the 3'-OH group cause disruption of the synthesis of a new DNA strain

Thymidine

Multi level prodrugs

Active uptake of α-Methyldopa-Phe by the dipeptide transporter

α-Methyldopa-Phe

first pass metabolism

α-Methyldopa

blood-brain barrier

amino acid transporter

decarboxylation

hydroxylisation

α-Methylnoreprinephrine

α-Methylnoreprinephrine is an α_2 agonist (false neurotransmitter)

Drug / Non-Drug Separation (1)

Is it possible to predict the potential suitability of a compound from typical properties of drugs ?

approaches:

Reckognition of typical properties in data bases that (almost) exclusively contain drugs

For example:

World Drug Index (WDI)

Comprehensive Medicinal Chemistry (CMC)

MACCS-II Drug Report (MDDR)

Drug / Non-Drug Separation (2)

Previous data base analyses:

1997 Christopher Lipinski's rule of 5 (Pfizer)

Orally administered drugs typically have

molecular weight < 500
ClogP < 5
less than 5 hydrogen-bond donors (O-H, N-H)
less than 10 hydrogen-bond acceptors (N, O, S)

2000 Tudor Oprea (AstraZeneca)

Typical drugs (70% of all) have

Lipinski's rule of 5 refers to oral bioavailability but not neccessarily drug-likeness !

less than 3 hydrogen-bond donors
between 2 and 9 hydrogen-bond acceptors
between 2 and 9 rotatable bonds
between 1 and 4 rings

Drug / Non-Drug Separation (3)

1999 Ghose, Viswanadhan & Wendoloski

Analysis of the Comprehensive Medicinal Chemistry database:

80% of all drugs have

160 < molecular weight < 480
–0.4 < logP < 5.6
20 < number of atoms < 70
40 < molar refractivity < 130

The preferred range covering 50% of all drugs shows

230 < molecular weight < 390
1.3 < logP < 4.1
30 < number of atoms < 55
70 < molar refractivity < 110

Lit: A. Ghose et al. *J.Comb.Chem.* **1** (1999) 55-68.

Drug / Non-Drug Separation (4)

Even tighter restrictions required to avoid adverse effects?

Molecular weight < 400 and ClogP < 4 (GSK 4/400 rule)

potency ————————→ So far the driving
membrane passage   force in drug design
toxicological issues
accumulation
promiscuity

solubility
bioavailability   „Start slim, stay fit"
CNS penetration   Michael M. Hann

higher

lower

logP, MW

Find smallest crucial parts of molecules → fragments

Lit: M.M. Hann „Molecular Obesity, Potency and Other Addictions
in Drug Discovery" *Med.Chem.Commun.* **2** (2011) 349-355.

Difficult and Undruggable Targets (1)

If there is no distinct binding pocket for typical small molecules, such targets are hard to inhibit:

Transcription Factors

Receptor Phosphatases

(soluble) Phosphatases

(K)RAS

RNA

Protein-Protein-Interaction

Lit: J.Wang et al. *Chin. J. Chem.* **37** (2019) 501.

Difficult and Undruggable Targets (2)

Many of those targets are, however, crucial in cancer therapy

Lit: J.S.Lazo & E.R.Sharlow *Annu.Rev.Pharmacol.Toxicol. Chem.* **56** (2016) 23.

Lifestyle vs. Disease

The great challenges

- Virostatics
- Antibiotics (Zn-β-lactamases, malaria)
- Anticancer drugs
- Neurodegenerative diseases (Antidementia, Alzheimer)
- Diabetes type 2
- civilization diseases (obesity, ADHD)?

Lifestyle vs. Disease (II)

The top selling drugs during recent times (selection):

adalimumab*   (arthritis)
apixaban   factor Xa-inhibitor (anti-coagulant)
pregabalin   calcium channels (epilepsy)
lenalidomide   antitumor/apoptisis
nivolumab*   (oncology, various cancers)
pembrolizumab*   (cancer immunotherapy)
etancercept*   (rheumatoid arthritis)
trastuzumab*   (breast cancer)
bevacizumab*   (colon cancer)
rituximab*   (autoimmune diseases, cancer)
sofosbuvir   antiviral nucleoside
fluticasone   anti-inflammatory/corticosteroid
rosuvastatin   HMG-CoA reductase

* monoclonal antibody   Source: wikipedia (2019)

Lifestyle vs. Disease (III)

Most „blockbuster" drugs were not predicted by analysts of the marketing departements:

	indication
tamoxifen	breast cancer
captopril	hypertension
cimetidine	gastric ulcers [Geschwulstbildung im Magen]
fluoxetine (Prozac™)	depression
atorvastatin (Lipitor™)	hyperlipidaemia, obesity

Lit: J.Knowles & G.Gromo *Nat.Rev.Drug.Discov.* **2** (2003) 63.

Lifestyle vs. Disease (IV)

Innovative new drugs that have emerged (source: Hugo Kubinyi)

2006	Deferasirox	iron chelator (thalassemia)
2003	Roflumilast	PDE-4 inhibitor (asthma)
2002	Ezetimib	cholesterol uptake inhibitor
2001	Imatinib	leucemia (tyrosine kinase inhibitor)
2001	Fondaparinux	thrombosis (antagonist)
1999	Zanamivir	influenza (viral neuraminase inhibitor)
1999	Amprenavir	HIV (protease inhibitor)
1999	Celecoxib	arthritis (COX-2 inhibitor)
1998	Sildenafil	erectile dysfunction (PDE-5 inhibitor)
1998	Orlistat	obesity (pancreas pipase inhibitor)
1997	Sibutramine	obesity (GPCR inhibitor)
1997	Finasteride	prostata (steroidreductase inhibitor)
1997	Nelfinavir	HIV (protease inhibitor)
1996	Indinavir	HIV (protease inhibitor)
1996	Nevirapin	HIV (reverse transcriptase inhibitor)

Lifestyle vs. Disease (V)

Innovative new drugs from 1982-1996:   (source: Hugo Kubinyi)

1996	Meloxicam	arthritis (COX-2 inhibitor)
1995	Dorzolamine	glaucoma (carboanhydrase inhibitor)
1995	Losartan	hypertension (GPCR antagonist)
1994	Famciclovir	herpes (DNA polymerase inhibitor)
1993	Risperidon	psychose (D_2 / $5HT_2$ antagonist)
1991	Sumatriptan	migraine ($5HT_1$ rezeptor antagonist)
1990	Ondansetron	antiemetic ($5HT_3$ antagonist)
1988	Omeprazole	gastric ulcers (proton pump inhibitor)
1987	Lovastatin	cholesterol (biosynthesis inhibitor)
1986	Artemisinin	anti-malarial (natural compound)
1985	Fluoxetine	depression (5HT inhibitor)
1985	Mefloquine	anti-malarial
1984	Enalapril	hypertension (ACE inhibitor)
1983	Cyclosporin A	immunosupressant
1982	Ranitidine	gastric ulcers (H_2 antagonist)

Lifestyle vs. Disease (VI)

How are innovative drugs defined ?

- improved mode of action (selectivity)
- improved ADMET profile
- Improved administration (e.g. oral instead of intravenous)
- pro-drugs
- new targets

personalized medicine

Variable metabolic content and predisposition
(Genotyping)

Avoiding rare, complicated adverse effects
(in part already used in the clinic)

Will the necessary financial effort of screening and of clinical
studies limit the genetic pool to inhibitants of wealthy nations ?

picture source: www.dana-farber.org

Resume

The available knowledge on the human genome and the present SNPs in it allow two approaches:

1. Finding new targets (either on the genome, the mRNA, or the protein level)

2. pharmacogenomic methods will lead to personalized medicine (which drug and at what dosage), esp. for long term application of certain drugs (hypertension, analgesics, anti-psychotics) and those that possess a narrow therapeutic band width (cardiotonics, antineoplastics)